Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Debiopharm S.A.
The Japanese firm has decided to shrink its oncology portfolio by transferring its rights to oxaliplatin in Japan, along with a portfolio of generics, to Takata. Though Yakult will maintain an interest in the area through irinotecan and several other anticancers, its has said future R&D investment will shift more towards the microbiome.
Plus deals involving Debiopharm/SunRock, RefleXion/3B Pharmaceuticals, Pharmanovia/Sanofi and more.
Public Company Edition: UroGen raised $120m in a private placement of ordinary shares. Also, Verrica entered into a debt financing for up to $125m upon approval of Ycanth for molluscum contagiosum and job cuts were announced by Homology, Mersana, Infinity and others.
The German firm is eyeing licensing opportunities in 2023 to fill up its mid-stage pipeline.
- Drug Delivery
- Other Names / Subsidiaries
- H3 Pharma
- Affinium Pharmaceuticals, Ltd.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.